Ursula A. Matulonis, MD, highlights the rationale behind studying mirvetuximab soravtansine (IMGN853) as a therapy for patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.
During The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, Ursula A. Matulonis, MD, Brock-Wilson Family Chair and chief of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute as well as professor of medicine at Harvard Medical School, spoke with CancerNetwork® about the rationale for assessing mirvetuximab soravtansine (IMGN853) in patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.
In particular, she highlights the population of the phase 3 SORAYA trial (NCT04296890), which included patients who had previously received bevacizumab (Avastin). She also stated that those with high-grade serous ovarian cancer are likely to have high levels of FRα, making them a potential good fit for treatment with mirvetuximab soravtansine.
Transcript:
This is a phase 3 study for patients with FRα-high, or FRα-positive, platinum-resistant ovarian cancer. Patients were required to have prior bevacizumab and they could [have received] up to 3 lines of prior treatment, and they could also have received PARP inhibitors. The rationale [behind this trial is rooted in the fact that] high-grade serous ovarian cancer is a cancer that has high levels of FRα. In high-grade serous [disease], high levels are present in about 40% of patients’ cancers. The rationale has been that in pooled trials, we’ve seen response rates that are near 30% in a very similarly designed and selected patient populations as in SORAYA.
Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression results from the SORAYA study. Presented at: 2022 SGO Annual Meeting on Womens’ Cancers; March 18-21, 2022; Phoenix, AZ. Abstract 242.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Early Intervention, Regular Assessment Can Grasp Symptom Course for Head and Neck Cancer Therapy
April 28th 2024Nurses must increase the frequency of their assessments for early intervention of patients who undergo treatment for their head and neck cancer, in an effort to truly individualized care.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.